CN107434827B - 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 - Google Patents

用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 Download PDF

Info

Publication number
CN107434827B
CN107434827B CN201710718246.6A CN201710718246A CN107434827B CN 107434827 B CN107434827 B CN 107434827B CN 201710718246 A CN201710718246 A CN 201710718246A CN 107434827 B CN107434827 B CN 107434827B
Authority
CN
China
Prior art keywords
leu
ala
glu
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201710718246.6A
Other languages
English (en)
Other versions
CN107434827A (zh
Inventor
周维宜
吴嘉茂
吴俊明
章修纲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TheVax Genetics Vaccine Co Ltd
Original Assignee
TheVax Genetics Vaccine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TheVax Genetics Vaccine Co Ltd filed Critical TheVax Genetics Vaccine Co Ltd
Publication of CN107434827A publication Critical patent/CN107434827A/zh
Application granted granted Critical
Publication of CN107434827B publication Critical patent/CN107434827B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/095—Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)

Abstract

本发明公开了一种疫苗组合物，其包含用于诱导增强的病原体抗原特异性T细胞反应的融合蛋白。所述融合蛋白包含：(a)抗原呈递细胞(APC)结合域或CD91受体结合域，其位于融合蛋白的N端；(b)长度为34‑112个氨基酸残基的转位肽，其包含与SEQ ID NO:4、SEQ ID NO:2、SEQ ID NO:3或SEQ ID NO:6至少90％相同的氨基酸序列，其位于APC结合域或CD91受体结合域的C端；(c)病原体的抗原，其位于转位肽的C端；(d)核输出信号，其包含SEQ ID NO:13的氨基酸序列；及(e)内质网滞留序列，其位于融合蛋白的C端。

Description

用作诱导抗原特异性T细胞反应的免疫原性增强剂的融合 蛋白
本申请为申请日为2013年12月3日，申请号为2013800638675以及发明名称为“用作诱导抗原特异性T细胞反应的免疫原性增强剂的融合蛋白”的专利申请的分案申请。
技术领域
本发明主要涉及融合蛋白及免疫学。
背景技术
分子生物学已使亚单位疫苗的制造成为可能，其中，免疫原为母蛋白或母复合物的片段或亚单位。所需要的是可诱发T细胞致敏反应又能足够灵活的并入来自许多感染源的毒株的序列的稳定疫苗的开发。
发明内容
一方面，本发明涉及一种融合蛋白，其包含：
(a)抗原呈递细胞(APC)结合域或CD91受体结合域，其位于所述融合蛋白的N端；
(b)长度为34-112个氨基酸残基的转位肽，其包含与SEQ ID NO:4、SEQ ID NO:2、SEQ ID NO:3或SEQ ID NO:6至少90％相同的氨基酸序列，其位于所述APC结合域或CD91受体结合域的C端；
(c)病原体的抗原，其位于所述转位肽的C端；
(d)核输出信号，其包含SEQ ID NO:13的氨基酸序列；及
(e)内质网(ER)滞留序列，其位于所述融合蛋白的C端。
在本发明的一个实施方式中，所述APC结合域或所述CD91受体结合域为多肽，其包含与选自SEQ ID NO:1及SEQ ID NO:8-SEQ ID NO:11的序列至少90％相同的氨基酸序列。
在本发明的另一个实施方式中，所述核输出信号包含SEQ ID NO:14的氨基酸序列。
在本发明的另一个实施方式中，所述内质网滞留序列包含SEQ ID NO:15的氨基酸序列。
在本发明的另一个实施方式中，所述核输出信号位于所述转位肽与所述抗原之间。
在本发明的另一个实施方式中，所述核输出信号位于所述抗原与所述内质网滞留序列之间。
在本发明的另一个实施方式中，所述核输出信号及所述ER滞留序列形成包含与SEQ ID NO:12至少90％相同的氨基酸序列的融合肽。
在本发明的另一个实施方式中，所述转位肽的长度为34-61个氨基酸残基。
在本发明的另一个实施方式中，所述转位肽的长度为34-46个氨基酸残基。
在本发明的另一个实施方式中，所述APC结合域或所述CD91受体结合域无假单胞菌外毒素A(PE)结合域I的氨基酸序列。
在本发明的另一个实施方式中，所述APC结合域或所述CD91受体结合域包含SEQID NO:8的氨基酸序列。
在本发明的另一个实施方式中，所述APC结合域或所述CD91受体结合域的氨基酸序列为SEQ ID NO:1。
在本发明的另一个实施方式中，所述抗原为病原体的两种或更多种抗原肽的融合抗原。
在本发明的另一个实施方式中，所述ER滞留序列的长度为多于4个氨基酸残基。
在本发明的另一个实施方式中，所述转位肽包含与SEQ ID NO:4、SEQ ID NO:2、SEQ ID NO:3或SEQ ID NO:6至少95％相同的氨基酸序列。
在本发明的另一个实施方式中，所述APC结合域或所述CD91受体结合域显示出识别并结合于选自树突细胞、单核细胞、B细胞及淋巴细胞的抗原呈递细胞(APC)上的受体的特征。
在本发明的另一个实施方式中，所述病原体选自PRRSV、PCV、FMDV、CSFV、NDV、传染性胃肠炎病毒(TGEV)、猪流行性腹泻病毒(PEDV)、流感病毒、假狂犬病病毒、细小病毒、假狂犬病病毒、猪水疱病毒(SVDV)、痘病毒、轮状病毒、支原体肺炎、疱疹病毒、传染性支气管炎及传染性粘液囊症病毒。
另一方面，本发明实质上由下列各项组成，或由下列各项组成：
(a)抗原呈递细胞(APC)结合域或CD91受体结合域，其位于所述融合蛋白的N端；
(b)长度为34-112个氨基酸残基转位肽，其包含与SEQ ID NO:4、SEQ ID NO:2、SEQID NO:3或SEQ ID NO:6至少90％相同的氨基酸序列，其位于所述APC结合域或CD91受体结合域的C端；
(c)病原体的抗原，其位于所述转位肽的C端；
(d)核输出信号，其包含SEQ ID NO:13的氨基酸序列；及
(e)内质网滞留序列，其位于所述融合蛋白的C端。
又一方面，本发明涉及一种包含前述融合蛋白及佐剂的疫苗组合物。
再一方面，本发明涉及一种用于诱导增强的病原体抗原特异性T细胞反应的方法，其包含：向有此需要的受试者施用包含治疗有效量的前述融合蛋白的疫苗组合物；并由此诱导增强的病原体抗原特异性T细胞反应。
本发明还涉及将前述融合蛋白或疫苗组合物用于诱导增强的病原体抗原特异性T细胞反应，或将前述融合蛋白用于制造诱导增强的病原体抗原特异性T细胞反应的药物。
附图说明
图1A为显示全长铜绿假单胞菌外毒素A(PE)及PE的部分片段的示意图。
图1B-C显示载体图谱。
图2-5分别为显示根据本发明的融合蛋白诱发增强的CD8+/IFN-γ+T细胞(图2A-5A)及CD4+/IFN-γ+T细胞(图2B-5B)介导的免疫原性的图。
图6显示动物组别、用于免疫所述动物的疫苗与剂量，以及免疫接种程序表。
图7-8分别为显示接种不同融合蛋白或安慰剂的动物组别的肿瘤大小曲线及无肿瘤小鼠百分比。
具体实施方式
由于对于本领域的技术人员来说在此的各种修改和变化将明显可见，所以在以下仅意欲用作说明的实施例中更具体地描述本发明。现在，将详述本发明的各种实施方式。参考附图，图中相同标号均代表相同部分。如在本说明书及随后的整个权利要求中使用的，除非上下文另外载明，否则“一”、“一个”和“该”的意思包括复数。并且，如在本说明书及随后的整个权利要求中使用的，除非上下文另外载明，否则“在…中”的意思包括“位于其中”及“位于其上”。此外，为读者的便利标题及小标题可以用于说明书中，其不影响本发明的范围。因此，以下将具体定义用于本说明书的若干术语。
定义
本说明书所使用的术语通常在本发明上下文内及使用各术语的特定上下文中具有它们在本领域中的常规涵义。用以描述本发明的特定用语将在下文中或在本说明书的别处加以说明，以向从业者提供有关本发明的描述的额外指导。为便利，某些术语可以例如使用斜体和/或引号突出显示，突出显示的使用不影响术语的范围与意义；无论是否突出显示，同一术语在相同上下文中的范围与意义皆相同。将意识到的是同一件事的表达方式不止一种。因此，替代用语及同义词可以用作任一一种或多种在此讨论的术语，也无任何特殊意义来归因于是否在此详细说明或讨论术语。本文提供某些术语之同义词。但使用某一或多个同义词并不表示排除其他同义词。本说明书的任何地方的实施例(包括在此处所讨论的术语的实施例)的使用仅为用作说明的，而非用于局限本发明或任何示例性术语的范围与意义。同样地，本发明并不局限于本说明书给出的各种实施方式。
除非另有定义，否则在此使用的所有技术与科学术语具有与本发明相关领域的普通技术者之一通常所了解的相同。在有相互冲突的情况下，则以本说明书及其所提供的定义为解释依据。
术语“抗原呈递细胞(APC)或辅助细胞”指呈现与其表面上的主要组织兼容性复合体(MHC)复合的外来抗原的细胞。T细胞可以使用它们的T细胞受体(TCR)来识别这些复合物。这些细胞加工抗原，并向T细胞呈递它们。专业抗原呈递细胞的主要种类为树突细胞(DC)、巨噬细胞(其亦为CD4+，因此易受HIV感染)、单核细胞及若干B细胞。
术语“抗原呈递细胞(APC)结合域”指可结合至抗原呈递细胞(APC)的区域(其为多肽)。所述APC结合域可为包含与选自SEQ ID NO:1及SEQ ID NO:8-SEQ ID NO:11的序列至少90％相同的氨基酸序列的多肽。APC结合域为可识别并结合于APC上的受体的配体。
分化簇91(CD91)为在细胞膜中形成受体且参与受体介导的内吞作用的蛋白。
术语“PEt”指长度为34-112个氨基酸残基的转位肽(或转位域)。PEt可包含与SEQID NO:2-SEQ ID NO:4及SEQ ID NO:6至少90％相同的氨基酸序列。例如，PEt的氨基酸序列可为PE的a.a.280-a.a.313片段(SEQ ID NO:4)、a.a.268-a.a.313片段(SEQ ID NO:3)、a.a.253-a.a.313片段(SEQ ID NO:2)或a.a.253-a.a.364片段(SEQ ID NO:6)。换言之，PEt的氨基酸序列可含有PE区域II(a.a.253至a.a.364；SEQ ID NO:6)的任一区，只要其包含a.a.280-a.a.313(SEQ ID NO:4)必需序列(即，必需片段)即可。
PE407(SEQ ID NO:7)在先前专利(美国专利第7,335,361B2号)中描述为PE(ΔIII)。
术语“最小转位肽”指PE253-313(SEQ ID NO:2)，其可将抗原转位至靶细胞的细胞质内。
术语“内质网(ER)滞留序列”指作用为帮助抗原从细胞质至ER的转位，并将所述抗原留在ER的内腔中的肽。ER滞留序列包含序列Lys Asp Glu Leu(KDEL；SEQ ID NO:15)或RDEL。ER滞留序列可包含序列KDEL、RDEL、KDELKDELKDEL(K3；SEQ ID NO:16)、KKDLRDELKDEL(K3；SEQ ID NO:17)、KKDELRDELKDEL(K3；SEQ ID NO:18)或KKDELRVELKDEL(K3；SEQ ID NO:19)。
核输出信号(NES)指蛋白中具有4个疏水性残基的短氨基酸序列，其为利用核传输，通过核孔复合体从细胞核输出至细胞质而靶向蛋白。输出蛋白(exportin)可识别并结合NES。疏水性残基最常见的间隔为LxxKLxxLxLx(SEQ ID NO:13)，其中，“L”为亮氨酸，“K”为赖氨酸，且“x”为任一种天然氨基酸。例如，人工NES可包含序列Leu Gln Lys Lys Leu GluGlu Leu Glu Leu Ala(LQKKLEELELA；SEQ ID NO:14)。
术语“NESK”指NES与ER滞留信号的融合肽(即，融合至ER滞留信号的NES)。NESK为具有核输出信号(NES)及ER滞留序列的功能的人工肽。因此，其可通过所述核孔复合体将抗原从细胞核输出至细胞质，并帮助抗原从细胞质转位至ER，而且将抗原留在ER的内腔中。例如，NESK的氨基酸序列可为LQKKLEELELAKDEL(SEQ ID NO:12)。
抗原可为病原体蛋白、多肽或肽，其为造成由所述病原体引起的疾病的原因，或可于所述病原体感染的宿主体内诱导免疫反应，或为多肽在肿瘤细胞内特异表达的肿瘤相关抗原(TAA)。所述抗原可选自病原体或癌症细胞，其包括但不限于人乳头瘤病毒(HPV)、猪繁殖及呼吸综合症病毒(PRRSV)、人类免疫缺陷病毒-1(HIV-1)、登革热病毒、丙型肝炎病毒(HCV)、乙型肝炎病毒(HBV)、猪环状病毒2(PCV2)、典型猪瘟病毒(CSFV)、口蹄疫病毒(FMDV)、新城病病毒(NDV)、传染性胃肠炎病毒(TGEV)、猪流行性腹泻病毒(PEDV)、流感病毒、假狂犬病病毒、细小病毒、假狂犬病病毒、猪水疱病毒(SVDV)、痘病毒、轮状病毒、支原体肺炎、疱疹病毒、传染性支气管炎、或传染性粘液囊症病毒、非小细胞肺癌、乳癌、黑色素瘤、淋巴瘤、结肠癌、肝细胞癌，及它们的组合。例如，HPV E7蛋白(E7)、HCV核心蛋白(HCV核心)、HBV X蛋白(HBx)选做开发疫苗的抗原。所述抗原可为选自一种或多种病原体蛋白的两种或更多种抗原)融合而成的融合抗原。例如，PRRSV ORF6与ORF5片段的融合抗原，或PRRSV与PCV2病原体的抗原蛋白的融合。
术语“治疗”或“疗法”指对已患癌症、或已遭受感染、或已出现倾向于该疾病的症状或易染病体质的有此需要的受试者施用有效量的融合蛋白，藉以治愈、减轻、解除、治疗、改善或预防疾病、其症状或倾向于它的易染病体质。基于任何适当诊断方法的结果能够识别出这样的受试者。
术语“有效量”指给予治疗的受试者产生治疗效果所需的活性化合物的量。如本领域中的技术人员所公认的，有效量将会根据施用途径、赋形剂的使用以及与其他治疗法共享的可能性而有所变化。
本发明涉及一种增强抗原递送并调节细胞介导的免疫反应的融合蛋白。所述融合蛋白包含：(a)抗原呈递细胞(APC)结合域或CD91受体结合域，其位于所述融合蛋白的N端；(b)长度为34-112个氨基酸残基的转位肽，其包含与SEQ ID NO:2至SEQ ID NO:4及SEQ IDNO:6至少90％相同的氨基酸序列，其位于所述APC结合域或CD91受体结合域的C端；(c)病原体的抗原，其位于所述转位肽的C端；(d)核输出信号(NES)；及(e)内质网(ER)滞留序列，所述ER滞留序列位于所述融合蛋白的C端，其中，NES包含SEQ ID NO:13的氨基酸序列。
以融合蛋白PE313-ORF2-NESK为例，策略在于本发明的融合蛋白刺激可识别第2型猪环状病毒(PCV2)壳体蛋白ORF2(抗原)的T细胞的制造与活化。融合蛋白自N端至C端依序包含PE区域I(APC结合域)，长度为34-112个氨基酸残基的转位肽(例如，PE区域II的a.a.253-313)，截短的PCV2ORF2蛋白(移除N端核定位信号)，NES信号，及ER滞留序列(KDEL)。以PE313-ORF2-NESK诱发增强的ORF2特异性T细胞免疫反应的基础机理包含下列步骤：a)结合至树突细胞(或抗原呈递细胞)表面受体(CD91)；b)由内吞作用内在化；c)传输至ER，并于转位肽前方以弗林蛋白酶进行蛋白质水解；d)加工，并通过MHC I复合体呈递；及e)活化抗原特异性CD4+及CD8+T细胞。CD4+Th1细胞可有效率地刺激并增强细胞毒性CD8+T细胞免疫反应。同时，适应性免疫系统的以上两种技术具有杀死PCV2及PCV2感染细胞的特异性和效力。
这里所述融合蛋白PE313-ORF2-NESK在许多方面均与Lai于美国专利第7,335,361号中公开的融合蛋白疫苗PE407-Ag-K3不同。首先，PE313(SEQ ID NO:5)的长度为94个氨基酸残基，比PE407(SEQ ID NO:7)短，其优点在于可将由PE的额外片段所诱发的不需要的体液反应降至最低。其次，缩短所述ER滞留序列。仅需要一个KDER或RDER而不需使用K3(即，3个KDER)。再者，仅细胞溶质抗原可被加工并经由MHC第I型通道呈递，因此，因为提高抗原移位进入细胞溶质的机会，将NES信号加入融合蛋白中有利于增强病原体抗原特异性T细胞反应。病原体的抗原可输入至细胞核内。通过结合NES信号，输入细胞核内的抗原便可通过融合蛋白的NES信号而输出至细胞质。
实施例
以下给出不意欲限制本发明的范围的根据本发明的实施方式的示例性仪器、设备、方法及其相关的结果。请注意，为读者的便利各标题或子标题用于实施例，其不应限制本发明的范围。此外，在此提出或公开某些理论；但是，只要本发明为据其本身实施而不考虑任何特定学说或实行方案，它们无论正确或错误，都不应限制本发明的范围。
实施例1
表达载体的构建
图1A显示PE含有3个区域(I、II及III)。PE407为PE从a.a.1至a.a 407的区域。PE407不含细胞毒素区域III，并且因此含有区域I及II。PE313为PE从a.a.1至a.a.313的区域，因此，PE313仅含有PE的区域Ia及区域II的部分N端区域。
图1B-C显示表达载体的结构，在有(下图)或无(上图)核输出信号(NES)的情况下，各结构均包含抗原呈递细胞(APC)结合域、转位肽、抗原；及内质网(ER)滞留序列(上图为K3或下图为K)，所述ER滞留序列位于融合蛋白的C端。如下产生质粒pTac-2-PE313-NESK、pTac-2-PE407-K3、pTac-2-RAP1-PE268-313-NESK及pTac-2-RAP1-PE268-313-K3：NdeIPE313-(EcoRI,XhoI)-NESKXhoI、NdeIPE407-(EcoRI,XhoI)-K3XhoI、NdeIRAP1-(EcoRI)-PE268-313-(EcoRI,XhoI)-NESKXhoI及NdeIRAP1-(EcoRI)-PE268-313-(EcoRI,XhoI)-K3XhoI片段以聚合酶连锁反应法(PCR)合成，然后利用卡那霉素抗药基因将其连接入pUC18骨干中以形成各质粒。
之后再将编码目的病原体的抗原或融合抗原的目标DNA插入前述质粒中以产生表达融合蛋白的表达载体。例如，合成编码第2型猪环状病毒(PCV2)ORF2(SEQ ID NO:20)、典型猪瘟病毒(CSFV)E2(SEQ ID NO:21)、口蹄疫病毒(FMDV)VP1-3A(SEQ ID NO:24)及新城病病毒(NDV)FHN(SEQ ID NO:27)的抗原的DNA片段并分别插入质粒pTac-2-PE313-NESK与pTac-2-PE407-K3中以产生下列表达载体：(1)PE313-ORF2-NESK；(2)PE407-ORF2-K3；(3)PE313-E2-NESK；(4)PE407-E2-K3；(5)PE313-VP1-3A-NESK；(6)PE407-VP1-3A-K3；(7)PE313-FHN-NESK及(8)PE407-FHN-K3。合成编码第16型人类乳头瘤病毒E7(SEQ ID NO:28)的抗原的DNA片段并分别插入质粒pTac-2-PE407-K3、pTac-2-RAP1-PE268-313-NESK及pTac-2-RAP1-PE268-313-K3中以产生下列表达载体：(9)PE407-E7-K3；(10)RAP1-PE268-313-E7-NESK及(11)RAP1-PE268-313-E7-K3。
实施例2
蛋白表达
在37℃下在含有25ppm卡那霉素的Luria Bertani培养基中分别培养含有用于融合蛋白(1)PE313-ORF2-NESK；(2)PE407-ORF2-K3；(3)PE313-E2-NESK；(4)PE407-E2-K3；(5)PE313-VP1-3A-NESK；(6)PE407-VP1-3A-K3；(7)PE313-FHN-NESK；(8)PE407-FHN-K3；(9)PE407-E7-K3；(10)RAP1-PE268-313-E7-NESK及(11)RAP1-PE268-313-E7-K3的表达的质粒的大肠杆菌(E.coli)BL21细胞。当培养基到达早期对数生长期(A600＝0.1至0.4)时，加入异丙基-1-硫代-β-D-半乳糖苷(IPTG)，使其最终浓度为0.5至2mM以达诱导的目的。诱导4小时后收集细胞，并且随即在-70℃下储存。所述融合蛋白以如前述的(Liao等人，1995，Appl.Microbiol.Biotechnol.43:498-507)尿素萃取法纯化，之后在4℃下，以50倍体积的TNE缓冲液(50mM Tris、50mM NaCl及1mM EDTA)进行隔夜透析，来再折叠。再折叠后的蛋白经过SDS-PAGE分析，并使用Bradford蛋白检测试剂盒(Pierce)进行定量分析。分析结果显示，大部分的再折叠蛋白在非还原条件下为单体，显示所述融合蛋白可轻易再折叠且未聚集。
实施例3
PCV2亚单位疫苗免疫原性分析
小鼠以每周一次、连续3周，经皮下注射接种0.1ml PCV2亚单位疫苗，疫苗含有40μg PE313-ORF2-NESK或PE407-ORF2-K3，以及磷酸铝(缓慢释放融合蛋白的蛋白质吸收剂；10％v/v)与10μg皂角苷(萃取自皂皮树(Quillaja saponaria)的佐剂)。对照组(安慰剂)仅注射佐剂而不注射融合蛋白。所有小鼠均在最后一次免疫后14天处死，并收集其脾脏。脾细胞经分离后，在37℃下及1μg/ml GolgiPlug(BD Pharmingen,San Diego,CA)存在的条件下，在含有或不含有重组ORF2蛋白的6孔培养板(108个细胞/2ml/孔)中培养16小时。刺激过后的脾细胞以FACScan缓冲液清洗，并以藻红蛋白共轭单克隆大鼠抗小鼠CD8a抗体及AF700共轭单克隆大鼠抗小鼠CD4抗体染色。使用根据制造商(BD Pharmingen)的说明的Cytofix/Cytoperm试剂盒进行细胞内细胞因子染色细胞。以AF488共轭大鼠抗小鼠IFN-γ染色细胞内的IFN-γ，以便量测免疫反应及细胞因子水平。使用Gallios流式细胞计数及Kaluza分析软件(Beckman Coulter)进行流式细胞计数分析。
图2A-B分别显示接种安慰剂(仅含佐剂而不含融合蛋白)或融合蛋白的小鼠的脾细胞中CD8+及CD4+IFN-γT细胞的数量。用ORF2刺激的脾细胞中由CD4+及CD8+T细胞所产生的IFN-γ通过经流式细胞计数的细胞内染色来检测。柱状图显示来自有(灰色柱)或没有(黑色柱)ORF2肽刺激的各组的ORF2特异性IFN-γ+CD4+T细胞的数量(图2B)及IFN-γ+CD8+T细胞的数量(图2A)。结果显示，已经接种PE313-ORF2-NESK的小鼠由ORF2肽刺激而产生的ORF2特异性CD4+IFN-γ+及CD8+IFN-γ+T细胞高于已经接种PE407-ORF2-K3的小鼠组。
实施例4
CSFV亚单位疫苗免疫原性分析
除了加入重组E2蛋白来刺激培养中的脾细胞之外，使用相同的免疫接种程序表及剂量为小鼠接种CSFV亚单位疫苗，其中亚单位疫苗含有PE313-E2-NESK或PE407-E2-K3，并且，分离、培养脾细胞，并以上述流式细胞计数法分析。
图3A-B分别显示接种安慰剂(仅含佐剂而不含融合蛋白)或融合蛋白的小鼠的脾细胞中CD8+及CD4+IFN-γT细胞的数量。用E2刺激的脾细胞中由CD4+及CD8+T细胞所产生的IFN-γ通过经流式细胞计数的细胞内染色来检测。柱状图显示来自有(灰色柱)或没有(黑色柱)E2肽刺激的各组的E2特异性IFN-γ+CD4+T细胞的数量(图3B)及IFN-γ+CD8+T细胞的数量(图3A)。结果显示，已经接种PE313-E2-NESK的小鼠由E2肽刺激而产生的E2特异性CD4+IFN-γ+及CD8+IFN-γ+T细胞高于已经接种PE407-E2-K3的小鼠组。
实施例5
FMDV亚单位疫苗免疫原性分析
除了加入重组VP1-3A蛋白来刺激培养中的脾细胞之外，使用相同的免疫接种程序表及剂量为小鼠接种FMDV亚单位疫苗，其中亚单位疫苗含有PE313-VP1-3A-NESK或PE407-VP1-3A-K3，并且，分离、培养脾细胞，并以上述流式细胞计数法分析。
图4A-B显示接种安慰剂或融合蛋白的小鼠的脾细胞中CD8+及CD4+IFN-γT细胞的数量。用VP1-3A刺激的脾细胞中由CD4+及CD8+T细胞所产生的IFN-γ通过经流式细胞计数的细胞内染色来检测。柱状图显示来自有(灰色柱)或没有(黑色柱)VP1-3A肽刺激的各组的VP1-3A特异性IFN-γ+CD4+T细胞的数量(图4B)及IFN-γ+CD8+T细胞的数量(图4A)。结果显示，已经接种PE313-VP1-3A-NESK的小鼠由VP1-3A肽刺激而产生的VP1-3A特异性CD4+IFN-γ+及CD8+IFN-γ+T细胞高于已经接种PE407-VP1-3A-K3的小鼠组。
实施例6
NDV亚单位疫苗免疫原性分析
除了加入重组FHN蛋白来刺激培养中的脾细胞之外，使用相同的免疫接种程序表及剂量为小鼠接种FMDV亚单位疫苗，其中亚单位疫苗含有PE313-FHN-NESK或PE407-FHN-K3，并且，分离、培养脾细胞，并以流式细胞计数法分析。
图5A-B显示接种安慰剂或融合蛋白的小鼠的脾细胞中CD8+及CD4+IFN-γT细胞的数量。用FHN刺激的脾细胞中由CD4+及CD8+T细胞所产生的IFN-γ通过经流式细胞计数的细胞内染色来检测。柱状图显示来自有(灰色柱)或没有(黑色柱)FHN肽刺激的各组的FHN特异性的IFN-γ+CD4+T细胞的数量(图5B)及IFN-γ+CD8+T细胞的数量(图5A)。结果显示，已经接种PE313-FHN-NESK的小鼠其经由FHN肽刺激而产生的FHN特异性CD4+IFN-γ+及CD8+IFN-γ+T细胞高于已经接种PE407-FHN-K3的小鼠组。
实施例7
由第16型人乳头瘤病毒E7蛋白诱导的肿瘤生长的增强的抑制
使用上述相似方法表达和再重叠所述融合蛋白PE407-E7-K3、RAP1-PE268-313-E7-K3及RAP1-PE268-313-E7-NESK。小鼠经皮下注射之用2x103个TC-01细胞(含有第16型HPV E7基因的小鼠肺部上皮细胞)激发，以诱导第16型HPV上皮癌。TC-01细胞激发后十二天，小鼠以每周一次、连续3周经皮下注射接种安慰剂(PBS)、PE407-E7-K3(100mg/剂)、RAP1-PE268-313-E7-K3(100μg/剂)或RAP1-PE268-313-E7-NESK(100μg/剂)(均以AS04C(GlaxoSmithKline)为佐剂)(图6)。AS04C为细胞毒性T淋巴细胞增强佐剂，包含MPL(单磷酯脂质A，一种免疫增效剂)及磷酸铝(一种用于抗原递送的蛋白质吸收剂)。术语“K3”指包含KDEL的ER滞留序列。例如，K3可为氨基酸序列KDELKDELKDEL(SEQ ID NO:16)。术语“NESK”指包含核输出信号及ER滞留序列的融合肽。在本发明的一个实施方式中，所述NESK为氨基酸序列LQKKLEELELAKDEL(SEQID NO:12)。记录各组的肿瘤大小及无肿瘤动物数(图7及8)。肿瘤生长由以AS04C为佐剂的疫苗PE407-E7-K3、RAP1-PE268-313-E7-K3及RAP1-PE268-313-E7-NESK显着抑制。但是，在抑制肿瘤生长及提高无肿瘤动物的百分比方面，疫苗RAP1-PE268-313-E7-NESK优于PE407-E7-K3，并且比RAP1-PE268-313-E7-K3更好。
实施例8
产生下列融合蛋白：PE313-NES-抗原-K、PE1-252-PE268-313-NES-抗原-K、PE1-252-PE280-313-NES-抗原-K。此外，融合蛋白PE313-抗原-NESK的PE区域Ia的片段(PE1-252)由RAP1区域3(SEQ ID NO:8)、A2M最小(SEQ ID NO:9)、HIV-Tat最小(SEQ ID NO:10)或HSPs最小(SEQID NO:11)代替以分别产生融合蛋白RAP1区域3-PE253-313-抗原-NESK、A2M-PE253-313-抗原-NESK、Tat-PE253-313-抗原-NESK及HSP-PE253-313-抗原-NESK、RAP1区域3-PE268-313-抗原-NESK、A2M-PE268-313-抗原-NESK、Tat-PE268-313-抗原-NESK及HSP-PE268-313-抗原-NESK疫苗、RAP1区域3-PE280-313-抗原-NESK、A2M-PE280-313-抗原-NESK、Tat-PE280-313-抗原-NESK及HSP-PE280-313-抗原-NESK。RAP1区域3-PE253-313-NES-抗原-K、A2M-PE253-313-NES-抗原-K、Tat-PE253-313-NES-抗原-K及HSP-PE253-313-NES-抗原-K、RAP1区域3-PE268-313-NES-抗原-K、A2M-PE268-313-NES-抗原-K、Tat-PE268-313-NES-抗原-K及HSP-PE268-313-NES-抗原-K疫苗、RAP1区域3-PE280-313-NES-抗原-K、A2M-PE280-313-NES-抗原-K、Tat-PE280-313-NES-抗原-K及HSP-PE280-313-NES-抗原-K。使用上述相似方法检测由这些疫苗增强的细胞介导的免疫反应。
表1显示制造各种融合蛋白所用肽的序列编号。
表1
Figure BDA0001384324040000121
Figure BDA0001384324040000131
*：粗体字母代表人工核输出信号的氨基酸序列；画线的字母代表内质网滞留信号的氨基酸序列。
**：VP1-3A肽为一种由VP1的a.a.127-a.a.176及3A的a.a.21-a.a.35组成的融合抗原；即，FMDV VP1肽(SEQ ID NO:22)及FMDV 3A肽(SEQ ID NO:23)的融合。
***：FHN肽为一种由融合蛋白的a.a.65-a.a.82及血凝素-神经氨酸酶的a.a.101-a.a.111组成的融合抗原；即，NDV F肽(SEQ ID NO:25)及NDV HN肽(SEQ ID NO:26)的融合。
总之，分析结果已证明含有位于N末端的APC结合域、转位域，并接续病原体的抗原，以及位于羧基末端的NESK融合肽的融合蛋白在增强细胞介导的免疫反应、抑制肿瘤生长和/或提高无肿瘤动物百分比方面为超过在羧基末端无NESK融合肽的PE-融合蛋白的改良的设计。
当已说明并描述本发明的实施方式时，本领域的技术人员可以进行各种修改和改善。本发明并不局限于说明的特定形式，并且所有未偏离本发明的实质与范围的修改均在所附权利要求定义的范围中。
选择并描述实施方式与实施例，以便解释本发明的原理及它们的实际应用，使本领域中的其他技术人员利用本发明及各种实施方式，和具有如适合实际预期使用的各种修改。有关本发明而不偏离其实质和范围的可选择的实施方式对于本领域的技术人员来说将明显可见。因此，本发明的范围由所附权利要求，而非由以上叙述及其中所描述的示例性实施方式定义。
在本发明的说明书中引用并讨论可能包括专利、专利申请案及各种出版物的参考文献。提供该参考文献的引用和/或讨论仅用来阐明本发明的说明，而非承认任一该参考文献为在此描述的本发明的“现有技术”。本说明书中所引用与讨论的所有参考文献，在此通过引用将其全部内容并入本文，且以如各参考文献分别通过引用并入的相同程度并入本文。
序列表
<110> 生控基因疫苗股份有限公司
<120> 用作诱导抗原特异性T细胞反应的免疫原性增强剂的融合蛋白
<130> 10021-00003
<150> 61733879
<151> 2012-12-05
<160> 29
<170> PatentIn version 3.5
<210> 1
<211> 252
<212> PRT
<213> 铜绿假单胞菌
<400> 1
Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val
1 5 10 15
Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro
20 25 30
Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val
35 40 45
Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu
50 55 60
Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu
65 70 75 80
Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser
85 90 95
Trp Ser Leu Asn Trp Leu Val Pro Ile Gly His Glu Lys Pro Ser Asn
100 105 110
Ile Lys Val Phe Ile His Glu Leu Asn Ala Gly Asn Gln Leu Ser His
115 120 125
Met Ser Pro Ile Tyr Thr Ile Glu Met Gly Asp Glu Leu Leu Ala Lys
130 135 140
Leu Ala Arg Asp Ala Thr Phe Phe Val Arg Ala His Glu Ser Asn Glu
145 150 155 160
Met Gln Pro Thr Leu Ala Ile Ser His Ala Gly Val Ser Val Val Met
165 170 175
Ala Gln Thr Gln Pro Arg Arg Glu Lys Arg Trp Ser Glu Trp Ala Ser
180 185 190
Gly Lys Val Leu Cys Leu Leu Asp Pro Leu Asp Gly Val Tyr Asn Tyr
195 200 205
Leu Ala Gln Gln Arg Cys Asn Leu Asp Asp Thr Trp Glu Gly Lys Ile
210 215 220
Tyr Arg Val Leu Ala Gly Asn Pro Ala Lys His Asp Leu Asp Ile Lys
225 230 235 240
Pro Thr Val Ile Ser His Arg Leu His Phe Pro Glu
245 250
<210> 2
<211> 61
<212> PRT
<213> 铜绿假单胞菌
<400> 2
Gly Gly Ser Leu Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro
1 5 10 15
Leu Glu Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu
20 25 30
Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala
35 40 45
Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg
50 55 60
<210> 3
<211> 46
<212> PRT
<213> 铜绿假单胞菌
<400> 3
Pro Leu Glu Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln
1 5 10 15
Leu Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu
20 25 30
Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg
35 40 45
<210> 4
<211> 34
<212> PRT
<213> 铜绿假单胞菌
<400> 4
Gly Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu Val
1 5 10 15
Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val
20 25 30
Ile Arg
<210> 5
<211> 313
<212> PRT
<213> 铜绿假单胞菌
<400> 5
Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val
1 5 10 15
Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro
20 25 30
Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val
35 40 45
Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu
50 55 60
Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu
65 70 75 80
Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser
85 90 95
Trp Ser Leu Asn Trp Leu Val Pro Ile Gly His Glu Lys Pro Ser Asn
100 105 110
Ile Lys Val Phe Ile His Glu Leu Asn Ala Gly Asn Gln Leu Ser His
115 120 125
Met Ser Pro Ile Tyr Thr Ile Glu Met Gly Asp Glu Leu Leu Ala Lys
130 135 140
Leu Ala Arg Asp Ala Thr Phe Phe Val Arg Ala His Glu Ser Asn Glu
145 150 155 160
Met Gln Pro Thr Leu Ala Ile Ser His Ala Gly Val Ser Val Val Met
165 170 175
Ala Gln Thr Gln Pro Arg Arg Glu Lys Arg Trp Ser Glu Trp Ala Ser
180 185 190
Gly Lys Val Leu Cys Leu Leu Asp Pro Leu Asp Gly Val Tyr Asn Tyr
195 200 205
Leu Ala Gln Gln Arg Cys Asn Leu Asp Asp Thr Trp Glu Gly Lys Ile
210 215 220
Tyr Arg Val Leu Ala Gly Asn Pro Ala Lys His Asp Leu Asp Ile Lys
225 230 235 240
Pro Thr Val Ile Ser His Arg Leu His Phe Pro Glu Gly Gly Ser Leu
245 250 255
Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu Thr Phe
260 265 270
Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly
275 280 285
Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser
290 295 300
Trp Asn Gln Val Asp Gln Val Ile Arg
305 310
<210> 6
<211> 112
<212> PRT
<213> 铜绿假单胞菌
<400> 6
Gly Gly Ser Leu Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro
1 5 10 15
Leu Glu Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu
20 25 30
Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala
35 40 45
Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu
50 55 60
Ala Ser Pro Gly Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln
65 70 75 80
Pro Glu Gln Ala Arg Leu Ala Leu Thr Leu Ala Ala Ala Glu Ser Glu
85 90 95
Arg Phe Val Arg Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn
100 105 110
<210> 7
<211> 407
<212> PRT
<213> 铜绿假单胞菌
<400> 7
Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val
1 5 10 15
Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro
20 25 30
Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val
35 40 45
Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu
50 55 60
Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu
65 70 75 80
Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser
85 90 95
Trp Ser Leu Asn Trp Leu Val Pro Ile Gly His Glu Lys Pro Ser Asn
100 105 110
Ile Lys Val Phe Ile His Glu Leu Asn Ala Gly Asn Gln Leu Ser His
115 120 125
Met Ser Pro Ile Tyr Thr Ile Glu Met Gly Asp Glu Leu Leu Ala Lys
130 135 140
Leu Ala Arg Asp Ala Thr Phe Phe Val Arg Ala His Glu Ser Asn Glu
145 150 155 160
Met Gln Pro Thr Leu Ala Ile Ser His Ala Gly Val Ser Val Val Met
165 170 175
Ala Gln Thr Gln Pro Arg Arg Glu Lys Arg Trp Ser Glu Trp Ala Ser
180 185 190
Gly Lys Val Leu Cys Leu Leu Asp Pro Leu Asp Gly Val Tyr Asn Tyr
195 200 205
Leu Ala Gln Gln Arg Cys Asn Leu Asp Asp Thr Trp Glu Gly Lys Ile
210 215 220
Tyr Arg Val Leu Ala Gly Asn Pro Ala Lys His Asp Leu Asp Ile Lys
225 230 235 240
Pro Thr Val Ile Ser His Arg Leu His Phe Pro Glu Gly Gly Ser Leu
245 250 255
Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu Thr Phe
260 265 270
Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly
275 280 285
Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser
290 295 300
Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser Pro Gly
305 310 315 320
Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu Gln Ala
325 330 335
Arg Leu Ala Leu Thr Leu Ala Ala Ala Glu Ser Glu Arg Phe Val Arg
340 345 350
Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp Val Val
355 360 365
Ser Leu Thr Cys Pro Val Ala Ala Gly Glu Cys Ala Gly Pro Ala Asp
370 375 380
Ser Gly Asp Ala Leu Leu Glu Arg Asn Tyr Pro Thr Gly Ala Glu Phe
385 390 395 400
Leu Gly Asp Gly Gly Asp Val
405
<210> 8
<211> 104
<212> PRT
<213> 人类
<400> 8
Ala Glu Phe Glu Glu Pro Arg Val Ile Asp Leu Trp Asp Leu Ala Gln
1 5 10 15
Ser Ala Asn Leu Thr Asp Lys Glu Leu Glu Ala Phe Arg Glu Glu Leu
20 25 30
Lys His Phe Glu Ala Lys Ile Glu Lys His Asn His Tyr Gln Lys Gln
35 40 45
Leu Glu Ile Ala His Glu Lys Leu Arg His Ala Glu Ser Val Gly Asp
50 55 60
Gly Glu Arg Val Ser Arg Ser Arg Glu Lys His Ala Leu Leu Glu Gly
65 70 75 80
Arg Thr Lys Glu Leu Gly Tyr Thr Val Lys Lys His Leu Gln Asp Leu
85 90 95
Ser Gly Arg Ile Ser Arg Ala Arg
100
<210> 9
<211> 153
<212> PRT
<213> 人工序列
<220>
<223> A2M 最小
<400> 9
Val Tyr Leu Gln Thr Ser Leu Lys Tyr Asn Ile Leu Pro Glu Lys Glu
1 5 10 15
Glu Phe Pro Phe Ala Leu Gly Val Gln Thr Leu Pro Gln Thr Cys Asp
20 25 30
Glu Pro Lys Ala His Thr Ser Phe Gln Ile Ser Leu Ser Val Ser Tyr
35 40 45
Thr Gly Ser Arg Ser Ala Ser Asn Met Ala Ile Val Asp Val Lys Met
50 55 60
Val Ser Gly Phe Ile Pro Leu Lys Pro Thr Val Lys Met Leu Glu Arg
65 70 75 80
Ser Asn His Val Ser Arg Thr Glu Val Ser Ser Asn His Val Leu Ile
85 90 95
Tyr Leu Asp Lys Val Ser Asn Gln Thr Leu Ser Leu Phe Phe Thr Val
100 105 110
Leu Gln Asp Val Pro Val Arg Asp Leu Lys Pro Ala Ile Val Lys Val
115 120 125
Tyr Asp Tyr Tyr Glu Thr Asp Glu Phe Ala Ile Ala Glu Tyr Asn Ala
130 135 140
Pro Cys Ser Lys Asp Leu Gly Asn Ala
145 150
<210> 10
<211> 24
<212> PRT
<213> 人工序列
<220>
<223> HIV-Tat 最小
<400> 10
Arg Gly Asp Pro Thr Gly Gln Glu Glu Ser Lys Glu Lys Val Glu Lys
1 5 10 15
Glu Thr Val Val Asp Pro Val Thr
20
<210> 11
<211> 641
<212> PRT
<213> 人工序列
<220>
<223> HSPs 最小
<400> 11
Met Ala Lys Ala Ala Ala Ile Gly Ile Asp Leu Gly Thr Thr Tyr Ser
1 5 10 15
Cys Val Gly Val Phe Gln His Gly Lys Val Glu Ile Ile Ala Asn Asp
20 25 30
Gln Gly Asn Arg Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu
35 40 45
Arg Leu Ile Gly Asp Ala Ala Lys Asn Gln Val Ala Leu Asn Pro Gln
50 55 60
Asn Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg Lys Phe Gly Asp
65 70 75 80
Pro Val Val Gln Ser Asp Met Lys His Trp Pro Phe Gln Val Ile Asn
85 90 95
Asp Gly Asp Lys Pro Lys Val Gln Val Ser Tyr Lys Gly Glu Thr Lys
100 105 110
Ala Phe Tyr Pro Glu Glu Ile Ser Ser Met Val Leu Thr Lys Met Lys
115 120 125
Glu Ile Ala Glu Ala Tyr Leu Gly Tyr Pro Val Thr Asn Ala Val Ile
130 135 140
Thr Val Pro Ala Tyr Phe Asn Asp Ser Gln Arg Gln Ala Thr Lys Asp
145 150 155 160
Ala Gly Val Ile Ala Gly Leu Asn Val Leu Arg Ile Ile Asn Glu Pro
165 170 175
Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Arg Thr Gly Lys Gly Glu
180 185 190
Arg Asn Val Leu Ile Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser
195 200 205
Ile Leu Thr Ile Asp Asp Gly Ile Phe Glu Val Lys Ala Thr Ala Gly
210 215 220
Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg Leu Val Asn His
225 230 235 240
Phe Val Glu Glu Phe Lys Arg Lys His Lys Lys Asp Ile Ser Gln Asn
245 250 255
Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Glu Arg Ala Lys Arg
260 265 270
Thr Leu Ser Ser Ser Thr Gln Ala Ser Leu Glu Ile Asp Ser Leu Phe
275 280 285
Glu Gly Ile Asp Phe Tyr Thr Ser Ile Thr Arg Ala Arg Phe Glu Glu
290 295 300
Leu Cys Ser Asp Leu Phe Arg Ser Thr Leu Glu Pro Val Glu Lys Ala
305 310 315 320
Leu Arg Asp Ala Lys Leu Asp Lys Ala Gln Ile His Asp Leu Val Leu
325 330 335
Val Gly Gly Ser Thr Arg Ile Pro Lys Val Gln Lys Leu Leu Gln Asp
340 345 350
Phe Phe Asn Gly Arg Asp Leu Asn Lys Ser Ile Asn Pro Asp Glu Ala
355 360 365
Val Ala Tyr Gly Ala Ala Val Gln Ala Ala Ile Leu Met Gly Asp Lys
370 375 380
Ser Glu Asn Val Gln Asp Leu Leu Leu Leu Asp Val Ala Pro Leu Ser
385 390 395 400
Leu Gly Leu Glu Thr Ala Gly Gly Val Met Thr Ala Leu Ile Lys Arg
405 410 415
Asn Ser Thr Ile Pro Thr Lys Gln Thr Gln Ile Phe Thr Thr Tyr Ser
420 425 430
Asp Asn Gln Pro Gly Val Leu Ile Gln Val Tyr Glu Gly Glu Arg Ala
435 440 445
Met Thr Lys Asp Asn Asn Leu Leu Gly Arg Phe Glu Leu Ser Gly Ile
450 455 460
Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu Val Thr Phe Asp Ile
465 470 475 480
Asp Ala Asn Gly Ile Leu Asn Val Thr Ala Thr Asp Lys Ser Thr Gly
485 490 495
Lys Ala Asn Lys Ile Thr Ile Thr Asn Asp Lys Gly Arg Leu Ser Lys
500 505 510
Glu Glu Ile Glu Arg Met Val Gln Glu Ala Glu Lys Tyr Lys Ala Glu
515 520 525
Asp Glu Val Gln Arg Glu Arg Val Ser Ala Lys Asn Ala Leu Glu Ser
530 535 540
Tyr Ala Phe Asn Met Lys Ser Ala Val Glu Asp Glu Gly Leu Lys Gly
545 550 555 560
Lys Ile Ser Glu Ala Asp Lys Lys Lys Val Leu Asp Lys Cys Gln Glu
565 570 575
Val Ile Ser Trp Leu Asp Ala Asn Thr Leu Ala Glu Lys Asp Glu Phe
580 585 590
Glu His Lys Arg Lys Glu Leu Glu Gln Val Cys Asn Pro Ile Ile Ser
595 600 605
Gly Leu Tyr Gln Gly Ala Gly Gly Pro Gly Pro Gly Gly Phe Gly Ala
610 615 620
Gln Gly Pro Lys Gly Gly Ser Gly Ser Gly Pro Thr Ile Glu Glu Val
625 630 635 640
Asp
<210> 12
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> NESK
<400> 12
Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Ala Lys Asp Glu Leu
1 5 10 15
<210> 13
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> NES 共有序列
<220>
<221> misc_feature
<222> (2)..(3)
<223> Xaa可为任一种天然氨基酸
<220>
<221> misc_feature
<222> (6)..(7)
<223> Xaa可为任一种天然氨基酸
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa可为任一种天然氨基酸
<220>
<221> misc_feature
<222> (11)..(11)
<223> Xaa可为任一种天然氨基酸
<400> 13
Leu Xaa Xaa Lys Leu Xaa Xaa Leu Xaa Leu Xaa
1 5 10
<210> 14
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> NES
<400> 14
Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Ala
1 5 10
<210> 15
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> ER滞留序列
<400> 15
Lys Asp Glu Leu
1
<210> 16
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> K3
<400> 16
Lys Asp Glu Leu Lys Asp Glu Leu Lys Asp Glu Leu
1 5 10
<210> 17
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> K3
<400> 17
Lys Lys Asp Leu Arg Asp Glu Leu Lys Asp Glu Leu
1 5 10
<210> 18
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> K3
<400> 18
Lys Lys Asp Glu Leu Arg Asp Glu Leu Lys Asp Glu Leu
1 5 10
<210> 19
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> K3
<400> 19
Lys Lys Asp Glu Leu Arg Val Glu Leu Lys Asp Glu Leu
1 5 10
<210> 20
<211> 192
<212> PRT
<213> 人工序列
<220>
<223> 截短的PCV2 ORF2
<400> 20
Asn Gly Ile Phe Asn Thr Arg Leu Ser Arg Thr Phe Gly Tyr Thr Ile
1 5 10 15
Lys Arg Thr Thr Val Lys Thr Pro Ser Trp Ala Val Asp Met Met Arg
20 25 30
Phe Asn Ile Asn Asp Phe Leu Pro Pro Gly Gly Gly Ser Asn Pro Arg
35 40 45
Ser Val Pro Phe Glu Tyr Tyr Ser Ile Ser Lys Val Lys Val Glu Phe
50 55 60
Trp Pro Cys Ser Pro Ile Thr Gln Gly Asp Ser Gly Val Gly Ser Ser
65 70 75 80
Ala Val Ile Leu Asp Asp Asn Phe Val Thr Lys Ala Thr Ala Leu Thr
85 90 95
Tyr Asp Pro Tyr Val Asn Tyr Ser Ser Arg His Thr Ile Thr Gln Pro
100 105 110
Phe Ser Tyr His Ser Arg Tyr Phe Thr Pro Lys Pro Val Leu Asp Ser
115 120 125
Thr Ile Asp Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu
130 135 140
Arg Leu Gln Thr Ala Gly Asn Val Asp His Val Gly Leu Gly Thr Ala
145 150 155 160
Phe Glu Asn Ser Ile Tyr Asp Gln Glu Tyr Asn Ile Arg Val Thr Met
165 170 175
Tyr Val Gln Phe Arg Glu Phe Asn Leu Lys Asp Pro Pro Leu Asn Pro
180 185 190
<210> 21
<211> 328
<212> PRT
<213> 人工序列
<220>
<223> 截短的CSFV E2
<400> 21
Arg Leu Ser Cys Lys Glu Asp His Arg Tyr Ala Ile Ser Ser Thr Asn
1 5 10 15
Glu Ile Gly Pro Leu Gly Ala Glu Gly Leu Thr Thr Thr Trp Lys Glu
20 25 30
Tyr Ser His Gly Leu Gln Leu Asp Asp Gly Thr Val Arg Ala Ile Cys
35 40 45
Ile Ala Gly Ser Phe Lys Val Thr Ala Leu Asn Val Val Ser Arg Arg
50 55 60
Tyr Leu Ala Ser Leu His Lys Arg Ala Leu Pro Thr Ser Val Thr Phe
65 70 75 80
Glu Leu Leu Phe Asp Gly Thr Ser Pro Ala Ile Glu Glu Met Gly Glu
85 90 95
Asp Phe Gly Phe Gly Leu Cys Pro Phe Asp Thr Thr Pro Val Val Lys
100 105 110
Gly Lys Tyr Asn Thr Thr Leu Leu Asn Gly Ser Ala Phe Tyr Leu Val
115 120 125
Cys Pro Ile Gly Trp Thr Gly Val Ile Glu Cys Thr Ala Val Ser Pro
130 135 140
Thr Thr Leu Arg Thr Glu Val Val Lys Thr Phe Lys Arg Glu Lys Pro
145 150 155 160
Phe Pro His Arg Ala Asp Cys Val Thr Thr Ile Val Glu Lys Glu Asp
165 170 175
Leu Phe His Cys Lys Leu Gly Gly Asn Trp Thr Cys Val Lys Gly Asn
180 185 190
Pro Val Thr Tyr Thr Gly Gly Gln Val Lys Gln Cys Arg Trp Cys Gly
195 200 205
Phe Asp Phe Lys Glu Pro Asp Gly Leu Pro His Tyr Pro Ile Gly Lys
210 215 220
Cys Ile Leu Ala Asn Glu Thr Gly Tyr Arg Val Val Asp Ser Thr Asp
225 230 235 240
Cys Asn Arg Asp Gly Val Val Ile Ser Thr Glu Gly Glu His Glu Cys
245 250 255
Leu Ile Gly Asn Thr Thr Val Lys Val His Ala Leu Asp Gly Arg Leu
260 265 270
Ala Pro Met Pro Cys Arg Pro Lys Glu Ile Val Ser Ser Ala Gly Pro
275 280 285
Val Arg Lys Thr Ser Cys Thr Phe Asn Tyr Thr Lys Thr Leu Arg Asn
290 295 300
Lys Tyr Tyr Glu Pro Arg Asp Ser Tyr Phe Gln Gln Tyr Met Leu Lys
305 310 315 320
Gly Glu Tyr Gln Tyr Trp Phe Asp
325
<210> 22
<211> 50
<212> PRT
<213> 人工序列
<220>
<223> FMDV VP1肽
<400> 22
Ala Thr Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Thr Ser Thr Ser
1 5 10 15
Asn Val Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Glu Arg Thr
20 25 30
Leu Pro Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Thr Arg Val Thr
35 40 45
Glu Leu
50
<210> 23
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> FMDV 3A肽
<400> 23
Ala Ala Ile Glu Phe Phe Glu Gly Met Val His Asp Ser Ile Lys
1 5 10 15
<210> 24
<211> 65
<212> PRT
<213> 人工序列
<220>
<223> FMDV VP1-3A肽
<400> 24
Ala Thr Val Tyr Asn Gly Ser Ser Lys Tyr Gly Asp Thr Ser Thr Ser
1 5 10 15
Asn Val Arg Gly Asp Leu Gln Val Leu Ala Gln Lys Ala Glu Arg Thr
20 25 30
Leu Pro Thr Ser Phe Asn Phe Gly Ala Ile Lys Ala Thr Arg Val Thr
35 40 45
Glu Leu Ala Ala Ile Glu Phe Phe Glu Gly Met Val His Asp Ser Ile
50 55 60
Lys
65
<210> 25
<211> 18
<212> PRT
<213> 人工序列
<220>
<223> NDV F肽
<400> 25
Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Gly Cys Ala Lys Ala Pro
1 5 10 15
Leu Glu
<210> 26
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> NDV HN肽
<400> 26
Pro Asp Glu Gln Asp Tyr Gln Ile Arg Met Ala
1 5 10
<210> 27
<211> 29
<212> PRT
<213> 人工序列
<220>
<223> NDV FHN肽
<400> 27
Leu Leu Pro Asn Met Pro Lys Asp Lys Glu Gly Cys Ala Lys Ala Pro
1 5 10 15
Leu Glu Pro Asp Glu Gln Asp Tyr Gln Ile Arg Met Ala
20 25
<210> 28
<211> 98
<212> PRT
<213> 人乳头瘤病毒第16型
<400> 28
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95
Lys Pro
<210> 29
<211> 613
<212> PRT
<213> 铜绿假单胞菌
<400> 29
Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val
1 5 10 15
Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro
20 25 30
Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val
35 40 45
Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu
50 55 60
Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu
65 70 75 80
Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser
85 90 95
Trp Ser Leu Asn Trp Leu Val Pro Ile Gly His Glu Lys Pro Ser Asn
100 105 110
Ile Lys Val Phe Ile His Glu Leu Asn Ala Gly Asn Gln Leu Ser His
115 120 125
Met Ser Pro Ile Tyr Thr Ile Glu Met Gly Asp Glu Leu Leu Ala Lys
130 135 140
Leu Ala Arg Asp Ala Thr Phe Phe Val Arg Ala His Glu Ser Asn Glu
145 150 155 160
Met Gln Pro Thr Leu Ala Ile Ser His Ala Gly Val Ser Val Val Met
165 170 175
Ala Gln Thr Gln Pro Arg Arg Glu Lys Arg Trp Ser Glu Trp Ala Ser
180 185 190
Gly Lys Val Leu Cys Leu Leu Asp Pro Leu Asp Gly Val Tyr Asn Tyr
195 200 205
Leu Ala Gln Gln Arg Cys Asn Leu Asp Asp Thr Trp Glu Gly Lys Ile
210 215 220
Tyr Arg Val Leu Ala Gly Asn Pro Ala Lys His Asp Leu Asp Ile Lys
225 230 235 240
Pro Thr Val Ile Ser His Arg Leu His Phe Pro Glu Gly Gly Ser Leu
245 250 255
Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu Thr Phe
260 265 270
Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly
275 280 285
Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser
290 295 300
Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser Pro Gly
305 310 315 320
Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro Glu Gln Ala
325 330 335
Arg Leu Ala Leu Thr Leu Ala Ala Ala Glu Ser Glu Arg Phe Val Arg
340 345 350
Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn Ala Asp Val Val
355 360 365
Ser Leu Thr Cys Pro Val Ala Ala Gly Glu Cys Ala Gly Pro Ala Asp
370 375 380
Ser Gly Asp Ala Leu Leu Glu Arg Asn Tyr Pro Thr Gly Ala Glu Phe
385 390 395 400
Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr Gln Asn
405 410 415
Trp Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg
420 425 430
Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln
435 440 445
Ser Ile Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu Asp Ala
450 455 460
Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly
465 470 475 480
Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg Asn Gly
485 490 495
Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly Phe Tyr
500 505 510
Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu
515 520 525
Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile Thr Gly
530 535 540
Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu
545 550 555 560
Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg
565 570 575
Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln
580 585 590
Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro Pro
595 600 605
Arg Glu Asp Leu Lys
610

Claims (11)

1.一种融合蛋白，其由下列结构组成：
(a)抗原呈递细胞(APC)结合域或CD91受体结合域，其位于所述融合蛋白的N端，所述APC结合域或CD91受体结合域选自由受体相关蛋白-1(RAP1)区域III、α-2-巨球蛋白受体相关蛋白(A2M)、HIV-Tat、热休克蛋白(HSP)及假单胞菌外毒素A(PE)结合域I所构成的群组；
(b)PE转位肽，其选自SEQ ID NO:4、SEQ ID NO:2、SEQ ID NO:3或SEQ ID NO:6的氨基酸序列，其位于所述APC结合域或CD91受体结合域的C端；
(c)病原体的抗原；
(d)核输出信号，其由SEQ ID NO:13的氨基酸序列所组成，其中所述SEQ ID NO:13的C端为丙氨酸(alanine)；及
(e)内质网(ER)滞留序列，其位于所述融合蛋白的C端；
其中，所述核输出信号位于所述抗原和所述内质网滞留序列之间，或所述转位肽和所述抗原之间，
其中：
所述病原体选自第16型人乳头瘤病毒(HPV16)、猪环状病毒2(PCV2)、典型猪瘟病毒(CSFV)、口蹄疫病毒(FMDV)、新城病病毒(NDV)中的一种。
2.如权利要求1所述的融合蛋白，其中，所述病原体的抗原选自由猪环状病毒2(PCV2)ORF2蛋白、典型猪瘟病毒(CSFV)E2蛋白、及第16型人乳头瘤病毒(HPV16)E7蛋白所构成的群组中的一种。
3.如权利要求2所述的融合蛋白，其中，所述PCV2 ORF2蛋白由SEQ ID NO:20的氨基酸序列所组成。
4.如权利要求2所述的融合蛋白，其中，所述CSFV E2蛋白由SEQ ID NO:21的氨基酸序列所组成。
5.如权利要求1所述的融合蛋白，其中，所述抗原为由口蹄疫病毒VP1(FMDV VP1)胜肽及口蹄疫病毒3A(FMDV 3A)肽融合而成的融合抗原，并且所述融合抗原由SEQ ID NO:24的氨基酸序列所组成。
6.如权利要求1所述的融合蛋白，其中，所述抗原为由新城病病毒F(NDV F)胜肽及新城病病毒血凝素-神经氨酸酶(NDV HN)肽融合而成的融合抗原，并且所述融合抗原由SEQ IDNO:27的氨基酸序列所组成。
7.如权利要求2所述的融合蛋白，其中，所述第16型人乳头瘤病毒(HPV16)E7蛋白由SEQID NO:28的氨基酸序列所组成。
8.一种融合蛋白，其由下列结构组成：
(a)抗原呈递细胞(APC)结合域或CD91受体结合域，其位于所述融合蛋白的N端，所述APC结合域或CD91受体结合域选自由受体相关蛋白-1(RAP1)区域III、α-2-巨球蛋白受体相关蛋白(A2M)、HIV-Tat、热休克蛋白(HSP)及假单胞菌外毒素A(PE)结合域I所构成的群组；
(b)PE转位肽，其选自SEQ ID NO:4、SEQ ID NO:2或SEQ ID NO:3的氨基酸序列，其位于所述APC结合域或CD91受体结合域的C端；
(c)病原体的抗原；
(d)核输出信号，其由SEQ ID NO:13的氨基酸序列所组成；及
(e)内质网(ER)滞留序列，其位于所述融合蛋白的C端；
其中，所述核输出信号位于所述抗原和所述内质网滞留序列之间，或所述转位肽和所述抗原之间，
其中：
所述病原体选自第16型人乳头瘤病毒(HPV16)、猪环状病毒2(PCV2)、典型猪瘟病毒(CSFV)、口蹄疫病毒(FMDV)、新城病病毒(NDV)中的一种。
9.如权利要求8所述的融合蛋白，其中所述病原体的抗原选自由猪环状病毒2(PCV2)ORF2蛋白、典型猪瘟病毒(CSFV)E2蛋白、及第16型人乳头瘤病毒(HPV16)E7蛋白所构成的群组中的一种。
10.如权利要求8所述的融合蛋白，其中所述抗原为由口蹄疫病毒VP1(FMDV VP1)胜肽及口蹄疫病毒3A(FMDV 3A)肽融合而成的融合抗原、或为由新城病病毒F(NDV F)胜肽及新城病病毒血凝素-神经氨酸酶(NDV HN)肽融合而成的融合抗原。
11.一种疫苗组合物，其包含如权利要求1或8的融合蛋白及佐剂。
CN201710718246.6A 2012-12-05 2013-12-03 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 Expired - Fee Related CN107434827B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733879P 2012-12-05 2012-12-05
US61/733,879 2012-12-05
CN201380063867.5A CN104884082B (zh) 2012-12-05 2013-12-03 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380063867.5A Division CN104884082B (zh) 2012-12-05 2013-12-03 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Publications (2)

Publication Number Publication Date
CN107434827A CN107434827A (zh) 2017-12-05
CN107434827B true CN107434827B (zh) 2020-09-11

Family

ID=50825669

Family Applications (7)

Application Number Title Priority Date Filing Date
CN201811287071.9A Pending CN109553688A (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201380063896.1A Expired - Fee Related CN104918637B (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201710718246.6A Expired - Fee Related CN107434827B (zh) 2012-12-05 2013-12-03 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201811287073.8A Expired - Fee Related CN109608550B (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201811287074.2A Pending CN109535259A (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201811288421.3A Expired - Fee Related CN109535228B (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201380063867.5A Expired - Fee Related CN104884082B (zh) 2012-12-05 2013-12-03 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201811287071.9A Pending CN109553688A (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201380063896.1A Expired - Fee Related CN104918637B (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201811287073.8A Expired - Fee Related CN109608550B (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201811287074.2A Pending CN109535259A (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201811288421.3A Expired - Fee Related CN109535228B (zh) 2012-12-05 2013-12-03 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN201380063867.5A Expired - Fee Related CN104884082B (zh) 2012-12-05 2013-12-03 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Country Status (12)

Country Link
US (4) US9481714B2 (zh)
EP (2) EP2928491B1 (zh)
JP (4) JP6173479B2 (zh)
KR (3) KR101746444B1 (zh)
CN (7) CN109553688A (zh)
BR (2) BR112015013135A2 (zh)
DK (1) DK2928491T3 (zh)
ES (2) ES2742739T3 (zh)
IL (2) IL239158A0 (zh)
RU (2) RU2619187C2 (zh)
TW (2) TWI490231B (zh)
WO (2) WO2014089036A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN109553688A (zh) * 2012-12-05 2019-04-02 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN107249629A (zh) * 2015-02-26 2017-10-13 生控基因疫苗股份有限公司 包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物
WO2016196383A1 (en) * 2015-06-01 2016-12-08 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
JP2018521983A (ja) 2015-07-16 2018-08-09 バイオカイン セラピューティックス リミテッド がんを治療するための組成物および方法
KR102153303B1 (ko) * 2015-11-23 2020-09-09 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 Fmdv 및 e2 융합 단백질 및 이의 용도
WO2018052854A1 (en) * 2016-09-19 2018-03-22 Thevax Genetics Vaccine Co., Ltd. Hepatitis b therapeutic vaccines
US11186618B2 (en) * 2016-09-21 2021-11-30 The Research Foundation For Microbial Diseases Of Osaka University Dendritic-cell-targeted peptide, fusion peptide utilizing said peptide, and vaccine utilizing said fusion peptide
CN107991481A (zh) * 2016-10-27 2018-05-04 武汉科前生物股份有限公司 一种检测猪伪狂犬病毒和口蹄疫病毒的二联阻断elisa抗体检测试剂盒及其应用
CN107937354A (zh) * 2017-11-10 2018-04-20 南京天邦生物科技有限公司 2型猪圆环病毒及其应用
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
CN109134667A (zh) * 2018-09-19 2019-01-04 天康生物股份有限公司 融合蛋白及其制备方法、应用、表达系统和疫苗
JP2022512976A (ja) 2018-11-07 2022-02-07 アプライド モレキュラー トランスポート インコーポレイテッド 異種ペイロードの経口送達のためのコリックス由来担体
CN109593136B (zh) * 2018-12-26 2021-03-19 天康生物股份有限公司 禽副粘病毒融合蛋白及其制备方法、应用和用于鸽子的apmv疫苗
KR20220012256A (ko) * 2019-05-24 2022-02-03 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
CN110051832B (zh) * 2019-05-31 2020-11-10 四川农业大学 一种犬恶丝虫病疫苗
CN110452928A (zh) * 2019-08-13 2019-11-15 成都天邦生物制品有限公司 一株pk-15稳定细胞株的构建及应用
AU2020329290A1 (en) * 2019-08-13 2022-03-24 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists
CN110669142B (zh) * 2019-09-30 2021-10-12 湖南农业大学 融合rgd的猪圆环病毒2型病毒样颗粒、突变型感染性克隆及其制备方法和应用
US20230173049A1 (en) * 2019-12-31 2023-06-08 The Johns Hopkins University Fusion proteins and methods of use thereof
CN111548395A (zh) * 2020-05-25 2020-08-18 中国农业科学院兰州兽医研究所 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用
KR102507298B1 (ko) 2020-12-21 2023-03-08 충남대학교산학협력단 면역증강을 위한 조성물
CN112812171B (zh) * 2021-01-22 2022-04-08 浙江辉肽生命健康科技有限公司 具有氨基酸结构vvrkplnkegkkp的生物活性肽及其制备方法和应用
CN114539429B (zh) * 2022-03-24 2022-07-29 上海普铭生物科技有限公司 融合蛋白组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969975A (zh) * 2008-01-31 2011-02-09 生宝美国公司 作为疫苗的hiv嵌合融合蛋白

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US843505A (en) * 1905-10-09 1907-02-05 Alexandre Leonard Tombelaine Safety closing device for miner's lamps.
PT651805E (pt) * 1992-07-17 2007-02-28 Dana Farber Cancer Inst Inc Método de ligação intracelular de moléculas-alvo
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
DK1000163T3 (da) * 1997-07-11 2006-02-06 Us Gov Health & Human Serv Pseudomonas-exotoksin A-lignende kimære immunogener
ATE359084T1 (de) * 1998-02-20 2007-05-15 Univ Miami Modifizierter hitzeschockprotein/peptidantigen komplex
WO1999045127A2 (en) * 1998-03-06 1999-09-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
WO2000049041A1 (fr) * 1999-02-19 2000-08-24 Sumitomo Electric Industries, Ltd. Preparations proteiques
JP4637368B2 (ja) * 1999-04-14 2011-02-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
EP1222289B1 (en) * 1999-10-20 2008-04-16 The Johns Hopkins University School Of Medicine Chimeric immunogenic compositions and nucleic acids encoding them
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
CA2453528C (en) * 2001-08-01 2011-07-26 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
US7235631B2 (en) * 2002-02-07 2007-06-26 Mayo Foundation For Medical Education And Research ICOS mutants
WO2004087754A1 (en) * 2003-04-03 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
IL164799A0 (en) * 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
CA2515123A1 (en) * 2003-02-04 2004-08-19 University Of Connecticut Health Center Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
EP1594437A2 (en) * 2003-02-04 2005-11-16 University of Connecticut Health Center Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
US7595054B2 (en) * 2003-06-09 2009-09-29 Healthbanks Biotech Co., Ltd. Fusion antigen used as vaccine
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
EP1756147A2 (en) * 2004-06-01 2007-02-28 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
JP4474264B2 (ja) * 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
WO2006135428A2 (en) * 2004-10-04 2006-12-21 Trinity Biosystems, Inc. Methods and compositions for inducing an immune response against multiple antigens
US7964200B2 (en) * 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
US7465455B2 (en) 2006-07-05 2008-12-16 Healthbanks Biotech Co., Ltd. Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine
WO2008047243A2 (en) * 2006-08-29 2008-04-24 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same
MX2009002893A (es) * 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US7887801B2 (en) * 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
WO2009036349A1 (en) * 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
EP2078726A1 (en) * 2008-01-09 2009-07-15 Vision 7 GmbH Secretable HIV entry inhibitory peptides for therapy of HIV infection
WO2010040023A2 (en) * 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
CN109553688A (zh) * 2012-12-05 2019-04-02 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969975A (zh) * 2008-01-31 2011-02-09 生宝美国公司 作为疫苗的hiv嵌合融合蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Analysis and prediction of leucine-rich nuclear export signals;Tanja la Cour et al;《Protein Enginerring, Design and Selection》;20041231;第17卷(第6期);527-536 *

Also Published As

Publication number Publication date
US9481714B2 (en) 2016-11-01
KR101671291B1 (ko) 2016-11-01
KR20160128431A (ko) 2016-11-07
KR20150097480A (ko) 2015-08-26
CN107434827A (zh) 2017-12-05
RU2619187C2 (ru) 2017-05-12
TW201428000A (zh) 2014-07-16
ES2742739T3 (es) 2020-02-17
US20140154280A1 (en) 2014-06-05
US20160229896A1 (en) 2016-08-11
BR112015013135A2 (pt) 2017-09-26
IL239158A0 (en) 2015-07-30
CN109553688A (zh) 2019-04-02
JP6400810B2 (ja) 2018-10-03
US20170029470A1 (en) 2017-02-02
WO2014089009A1 (en) 2014-06-12
US9676827B2 (en) 2017-06-13
CN109608550A (zh) 2019-04-12
DK2928491T3 (en) 2019-01-14
EP2928491A4 (en) 2016-07-13
JP2018030843A (ja) 2018-03-01
CN109535228B (zh) 2020-09-11
EP2928493A1 (en) 2015-10-14
US20140154285A1 (en) 2014-06-05
EP2928491B1 (en) 2018-11-21
TWI486359B (zh) 2015-06-01
IL239157A0 (en) 2015-07-30
CN109608550B (zh) 2020-09-11
JP6449384B2 (ja) 2019-01-09
CN104918637A (zh) 2015-09-16
ES2701448T3 (es) 2019-02-22
JP6173479B2 (ja) 2017-08-02
EP2928493B1 (en) 2019-08-07
CN109535259A (zh) 2019-03-29
US9676826B2 (en) 2017-06-13
CN109535228A (zh) 2019-03-29
RU2015122368A (ru) 2017-01-13
TW201428001A (zh) 2014-07-16
KR101650364B1 (ko) 2016-08-23
KR101746444B1 (ko) 2017-06-13
EP2928491A1 (en) 2015-10-14
CN104918637B (zh) 2018-12-11
JP2016504308A (ja) 2016-02-12
CN104884082B (zh) 2017-09-22
BR112015013183A2 (pt) 2017-09-26
CN104884082A (zh) 2015-09-02
RU2015122371A (ru) 2017-01-13
RU2631002C2 (ru) 2017-09-15
WO2014089036A1 (en) 2014-06-12
JP2017222673A (ja) 2017-12-21
KR20150097479A (ko) 2015-08-26
JP6279606B2 (ja) 2018-02-14
TWI490231B (zh) 2015-07-01
JP2016504309A (ja) 2016-02-12
EP2928493A4 (en) 2017-01-04
US9339536B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
CN107434827B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN107847575B (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200911

Termination date: 20211203